Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.

Journal: Clinical lymphoma, myeloma & leukemia

PMID: 29273217

Abstract

BACKGROUND: Severe immune dysregulation such as seen in autoimmune (AI) disease is known to act as a significant risk factor for diffuse large B-cell lymphoma (DLBCL). However, little is known about the demographics or clinical outcomes of DLBCL that arises in the setting of AI disease.

Authors

Jean L Koff

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address: jkoff@emory.edu.
Ashish Rai

American Cancer Society, Atlanta, GA.
Christopher R Flowers

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.

Keywords

Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols Arthritis, Rheumatoid Autoimmune Diseases Comorbidity Female Humans Lupus Erythematosus, Systemic Lymphoma, Large B-Cell, Diffuse Male Medicare Retrospective Studies SEER Program Sjogren's Syndrome Survival Analysis United States

External Resources

View on PubMed Access via DOI PubMed (29273217)

Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals